EUVIMEDEUVIMED entdecken
Open Access

H3K9 demethylase KDM3A potentiates interferon signaling and macrophage-driven inflammation in atherosclerosis

Ricky Siebeler iD, Hung-Jen Chen iD, Tatyana Kuznetsova, Annette E Neele iD, Saskia van der Velden iD, Marion J J Gijbels iD, Guillermo R Griffith iD, Cindy P A A van Roomen, Koen H M Prange iD, Marieke C S Boshuizen, Tom T P Seijkens, Kaylin C A Palm und 4 weitere

Science Advances · 13.11.2026 · 12 (46)

DOI: 10.1126/sciadv.aei2659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 13.11.2026. Verfasst von Ricky Siebeler und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, University of Amsterdam, Amsterdam UMC, Location AMC, Meibergdreef 9, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Jumonji Domain-Containing Histone Demethylases, Macrophages, Atherosclerosis, Signal Transduction. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Netherlands Heart Foundation, ZonMW, NWO VENI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrophages drive atherosclerosis through inflammatory activation programs shaped by metabolic and epigenetic reprogramming. H3K9 methylation enforces heterochromatin states and represses transcription, whereas removal of this histone modification creates transcriptionally permissive chromatin. Here, we identified KDM3A-mediated H3K9 demethylation to enhance chromatin accessibility at interferon (IFN) signaling loci, thereby promoting IFN production and downstream IFN-dependent transcriptional and chemokine responses. In a mouse model of atherosclerosis, hematopoietic Kdm3a deficiency reduces lesion size, necrotic core formation, and neutrophil recruitment. Mechanistically, Kdm3a -deficient macrophages show impaired chemokine secretion and reduced neutrophil recruitment both in vitro and in vivo. In primary human macrophages, KDM3A knockdown suppressed IFN responses; consistently KDM3A-dependent gene signatures were enriched in IFN-inducible macrophages within human atherosclerotic plaques, and computational modeling predicted a shift toward more stable plaque phenotypes upon KDM3A inhibition. Together, these findings establish KDM3A as an epigenetic regulator that sustains IFN-driven macrophage activation and promotes progression of atherosclerosis, nominating KDM3A as a potential target for selectively modulating IFN-dependent inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Jumonji Domain-Containing Histone DemethylasesMacrophagesAtherosclerosisSignal TransductionInflammationInterferonsAnimalsHumansMiceDisease Models, AnimalHistonesMice, Knockout

Substanzen

Jumonji Domain-Containing Histone DemethylasesInterferonsHistonesKdm3a protein, mouseKDM3A protein, human

Autor:innen und Institutionen

  • Department of Medical Biochemistry, University of Amsterdam, Amsterdam UMC, Location AMC, Meibergdreef 9, Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences (ACS), Atherosclerosis and Aortic Disease, Amsterdam UMC, Amsterdam, The Netherlands.
  • Amsterdam Institute for Immunology and Infectious Diseases (AII), Inflammatory Diseases, Amsterdam UMC, Amsterdam, The Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Pathology CARIM, Cardiovascular Research Institute Maastricht, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
  • Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: Ricky Siebeler, Hung-Jen Chen, Annette E Neele, Saskia van der Velden, Marion J J Gijbels, Guillermo R Griffith, Koen H M Prange, Michal Mokry, Esther Lutgens, Marten A Hoeksema, Menno P J de Winther

Förderung

  • The Netherlands Heart Foundation
  • ZonMW
  • NWO VENI
  • European Union (EU) Horizon 2020 program EPIMAC
  • Spark-Holding BV
  • Fondation Leducq (Transatlantic Network Grant
  • the EU Horizon 2020 program REPROGRAM
  • European Union

Zitieren

APA

Siebeler, R., Chen, H. J., Kuznetsova, T., Neele, A. E., van der Velden, S., Gijbels, M. J. J., Griffith, G. R., van Roomen, C. P. A. A., Prange, K. H. M., Boshuizen, M. C. S., Seijkens, T. T. P., Palm, K. C. A., Mokry, M., Lutgens, E., Hoeksema, M. A., & de Winther, M. P. J. (2026). H3K9 demethylase KDM3A potentiates interferon signaling and macrophage-driven inflammation in atherosclerosis. Science Advances, 12(46). https://doi.org/10.1126/sciadv.aei2659

Vancouver

Siebeler R, Chen HJ, Kuznetsova T, Neele AE, van der Velden S, Gijbels MJJ, et al. H3K9 demethylase KDM3A potentiates interferon signaling and macrophage-driven inflammation in atherosclerosis. Science Advances. 2026;12(46). doi:10.1126/sciadv.aei2659

BibTeX
@article{Siebeler2026,
  author = {Siebeler, Ricky and Chen, Hung-Jen and Kuznetsova, Tatyana and Neele, Annette E and van der Velden, Saskia and Gijbels, Marion J J and Griffith, Guillermo R and van Roomen, Cindy P A A and Prange, Koen H M and Boshuizen, Marieke C S and Seijkens, Tom T P and Palm, Kaylin C A and Mokry, Michal and Lutgens, Esther and Hoeksema, Marten A and de Winther, Menno P J},
  title = {H3K9 demethylase KDM3A potentiates interferon signaling and macrophage-driven inflammation in atherosclerosis},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {46},
  doi = {10.1126/sciadv.aei2659}
}
Kostenlos starten →